Related Experiment Video
Updated: Nov 15, 2025
10:27
Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
Published on: December 15, 2011
24.7K
Immunologic overlap in a case of linear IgG/IgA bullous dermatosis responsive to rituximab
Dmitry Nedosekin1, Kelsey Derrick Wilson2, Katelynn Campbell3
1College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
JAAD Case Reports
|March 5, 2021
Abstract
No abstract available in PubMed .
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
290
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
290
00:42Cross-reactivity
32.1K
Overview
32.1K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
317
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
317